4 completed, 2 terminated, 1 recruiting, 1 suspended. 5 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Suspended 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Recurrent Hematologic Malignancy: new trials by email Literature Review of Recurrent Hematologic Malignancy trials Research Report on Recurrent Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning Internet-Based Intervention, Best Practice, Telephone-Based Intervention - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 400 | 2025-02-18 | 2026-08-17 |
| Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer Survey Administration - Advanced Malignant Solid Neoplasm, COVID-19 Infection | Completed | M.D. Anderson Cancer Center | 223 | 2021-04-27 | 2024-09-19 | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Fructooligosaccharide, Laboratory Biomarker Analysis - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy | Phase 1 | Completed | Stanford University | 15 | 2016-06-01 | 2021-03-23 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 71 | 2013-05-16 | 2021-06-24 |
Hematologic Neoplasms (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Hodgkin Disease (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myeloid, Acute (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Neoplasm Metastasis (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Leukemia, Hairy Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Mastocytosis, Systemic (2) · Myeloproliferative Disorders (2) · Anemia (1)
Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Neoplasms by Site (9) · Neoplasms (8) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia (6) · Leukemia, Lymphoid (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (5) · Leukemia, Myeloid (5)
CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Acetaminophen (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Bortezomib (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1)
City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Rutgers, The State University of New Jersey (1) · Stanford University (1) · University of Chicago (1)
United States (8)
Andrew Rezvani (1) · David Hui, MD (1) · Hongtao Liu (1) · Ibrahim Aldoss, MD (1) · Ibrahim T Aldoss (1) · Lara Davis, MD (1) · Matthew S Davids (1) · Megan J Shen, PhD (1) · Roger Strair (1) · Tessa Andermann (1)
PMID 27410923, PMID 32478814, PMID 33720354, PMID 35622074, PMID 39863139
P30CA006516 (1), P30CA014599 (1), P30CA033572 (1), P30CA072720 (1), P30CA124435 (1), R01CA183559 (1), R37CA246703 (1), U01CA062490 (1), UM1CA186709 (1)